A Phase 2 interventional study of Placebo and BYM338 in Chronic Obstructive Pulmonary Disease (COPD) With Cachexia, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 3 countries. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Novartis.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 86th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 21 in phase 2, and was the 65th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 26 · Phase 3 61 · Phase 4 24
First in 2003; this study’s year is marked. 22 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 203 across the 116 interventional studies, 103 across the 1 observational. Of the 110 that completed or were terminated, 94 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo. The study will last for approximately 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BYM338
Drug: Placebo
BYM338
Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24
Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 4,8,16 and 24 was considered responders.
Time frame: Baseline, Weeks 4, 8, 16, 24
Change in 6 Minute Walk Distance Compared to Placebo
Practical simple test that requires a 100-ft hallway but no exercise quipment or advanced training for technicians. Walking is an activity performed daily by all but the most severely impaired patients. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD)
Time frame: Baseline, Weeks 4, 8, 16, 24
Maximum Observed Serum Concentration (Cmax)
The observed maximum plasma concentration following drug administration
Time frame: 0 hour, 2 hour, Day 8, 15, 29, 57, 71, 85, 99, 113, 127, 168 post dose
Time to Reach the Maximum Concentration After Drug Administration (Tmax)
The time to reach the maximum concentration after drug administration
Time frame: 24 weeks
AUC0-56 and AUClast
AUC0-56, the area under the serum concentration-time curve from the time zero to the end of the dosing interval, day 56. AUC0-56 was analyzed for dose 1 and 2. AUClast is from time zero to the last quantifiable concentration. AUClast was analyzed for dose 2 only.
Time frame: 0 hour, 2 hour, Day 8, 15, 29, 57, 71, 85, 99, 113, 127, 168 post dose
| Milestone | BYM338 | Placebo |
|---|---|---|
| Started | 33 | 34 |
| Completed | 27 | 28 |
| Not completed | 6 | 6 |
| Withdrew: Subject withdrew consent | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Administrative problems | 1 | 2 |
Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 4,8,16 and 24 was considered responders.
| Percentage Change of TMV | BYM338 | Placebo |
|---|---|---|
| Week 4 Day 29 (n=30,31) | 5.87 ± 3.413 | 0.02 ± 3.261 |
| Week 8 Day 57 (n=27,27) | 7.01 ± 3.707 | -0.65 ± 2.752 |
| Week 16 Day 113 (27,28) | 7.84 ± 5.052 | -0.88 ± 4.471 |
| End of Study, week 24 (n=27,28) | 5.04 ± 4.872 | -1.31 ± 4.282 |
Practical simple test that requires a 100-ft hallway but no exercise quipment or advanced training for technicians. Walking is an activity performed daily by all but the most severely impaired patients. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD)
| meter | BYM338 | Placebo |
|---|---|---|
| Week 4 Day 29 (n=30,32) | 364.6 ± 85.45 | 388.5 ± 100.22 |
| Week 8 Day 57 (n=27,29) | 373.9 ± 101.42 | 387.4 ± 99.73 |
| Week 12 Day 85 (n=27,28) | 383.0 ± 84.63 | 385.6 ± 107.62 |
| Week 16 Day 113 (n=25,28) | 379.7 ± 83.78 | 352.9 ± 104.01 |
| End of Study week 24 (n=27, 28) | 374.9 ± 98.29 | 378.8 ± 81.50 |
The observed maximum plasma concentration following drug administration
| ug/mL | BYM338 |
|---|---|
| Cmax dose 1 (n=31) | 614 ± 143 |
| Cmax dose 2 (n=26) | 580 ± 121 |
The time to reach the maximum concentration after drug administration
| hr | BYM338 |
|---|---|
| Tmax dose 1 (n=31) | 2.22 ± NA |
| Tmax dose 2 (n=26) | 2.23 ± NA |
AUC0-56, the area under the serum concentration-time curve from the time zero to the end of the dosing interval, day 56. AUC0-56 was analyzed for dose 1 and 2. AUClast is from time zero to the last quantifiable concentration. AUClast was analyzed for dose 2 only.
| day*ug/mL | BYM338 |
|---|---|
| AUC0-56 dose 1 (n=26) | 4540 ± 897 |
| AUC0-56 dose 2 (n=25) | 5790 ± 1300 |
| AUClast dose 2 (n=25) | 7480 ± 2080 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338 30mg/kg | — | 4/33 (12.1%) | 31/33 (93.9%) |
| Placebo | — | 3/34 (8.8%) | 30/34 (88.2%) |
| Event | BYM338 30mg/kg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 2/33 | 1/34 |
| Inguinal herniaGastrointestinal disorders | 1/33 | 0/34 |
| Postoperative wound infectionInfections and infestations | 1/33 | 0/34 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 1/33 | 0/34 |
| Hip fractureInjury, poisoning and procedural complications | 1/33 | 0/34 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/33 | 0/34 |
| Throat cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/33 | 0/34 |
| Haemorrhage intracranialNervous system disorders | 1/33 | 0/34 |
| HaematuriaRenal and urinary disorders | 1/33 | 0/34 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/33 | 0/34 |
| Event | BYM338 30mg/kg | Placebo |
|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 26/33 | 16/34 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 18/33 | 5/34 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 16/33 | 12/34 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 15/33 | 9/34 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/33 | 7/34 |
| HeadacheNervous system disorders | 3/33 | 8/34 |
| DiarrhoeaGastrointestinal disorders | 7/33 | 3/34 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/33 | 6/34 |
| PruritusSkin and subcutaneous tissue disorders | 5/33 | 7/34 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/33 | 5/34 |
| Age, Continuous(Years) | BYM338 | Placebo | Total |
|---|---|---|---|
| Mean | 64.5 ± 5.93 | 63.1 ± 7.51 | 63.7 ± 6.76 |
| Sex: Female, Male(Participants) | BYM338 | Placebo | Total |
|---|---|---|---|
| Female | 16 | 18 | 34 |
| Male | 17 | 16 | 33 |
The record gives a start of Sep 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab
Pulmonary Disease, Chronic Obstructive →